loader image

We are minovia

Minovia Therapeutics is the first company to use cell therapy to treat mitochondrial diseases, through our Mitochondrial Augmentation Therapy (MAT) platform. Our initial clinical focus is on rare mitochondrial diseases for which there are no approved treatments. Following a compassionate use program we are accelerating the clinical development and science to bring MAT to those who need it most. Minovia is now conducting a Phase I/II clinical trial in Pearson Syndrome.